Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis
Females with Cystic Fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males
Speeding up access to new drugs for Cystic Fibrosis: Considerations for clinical trial design and delivery
Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding